|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9374
|
|
pubmed:dateCreated |
2003-6-19
|
|
pubmed:abstractText |
Many patients with multiple sclerosis do not respond to interferon beta, which is widely used as an immunomodulatory treatment in this disease. We aimed to assess the functional relevance of tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), which is upregulated on incubation with interferon beta, for clinical treatment response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Apoptosis Regulatory Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/TNF-Related Apoptosis-Inducing...,
http://linkedlifedata.com/resource/pubmed/chemical/TNFSF10 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:AktasOrhanO,
pubmed-author:Bellmann-StroblJudithJ,
pubmed-author:EhrlichStefanS,
pubmed-author:GrundströmEvaE,
pubmed-author:LünemannJan DJD,
pubmed-author:VolkHans-DieterHD,
pubmed-author:WandingerKlaus-PeterKP,
pubmed-author:WeberAlexandraA,
pubmed-author:WengertOliverO,
pubmed-author:WerneckeKlaus-DKD,
pubmed-author:ZippFraukeF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
14
|
|
pubmed:volume |
361
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2036-43
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12814715-Adjuvants, Immunologic,
pubmed-meshheading:12814715-Adolescent,
pubmed-meshheading:12814715-Adult,
pubmed-meshheading:12814715-Apoptosis Regulatory Proteins,
pubmed-meshheading:12814715-Biological Markers,
pubmed-meshheading:12814715-Female,
pubmed-meshheading:12814715-Gene Expression Regulation,
pubmed-meshheading:12814715-Humans,
pubmed-meshheading:12814715-Interferon-beta,
pubmed-meshheading:12814715-Ligands,
pubmed-meshheading:12814715-Male,
pubmed-meshheading:12814715-Membrane Glycoproteins,
pubmed-meshheading:12814715-Middle Aged,
pubmed-meshheading:12814715-Multiple Sclerosis,
pubmed-meshheading:12814715-TNF-Related Apoptosis-Inducing Ligand,
pubmed-meshheading:12814715-Tumor Necrosis Factor-alpha,
pubmed-meshheading:12814715-Up-Regulation
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.
|
|
pubmed:affiliation |
Institute of Neuroimmunology, Charité University Hospital, Schumannstrasse 20/21, 10117, Berlin, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
